klh-2109

Small moleculeexperimental

Clinical trial activity

7 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
7
Phase 3
3
Phase 4
0

Earliest trial started Jul 14, 2011 (NCT01395940)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • klh-2109
  • klh-2109

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07015268Phase 3Jun 30, 2025Kissei Pharmaceuticals
NCT05440383Phase 3Oct 11, 2022Kissei Pharmaceuticals
NCT05445167Phase 3Oct 11, 2022Kissei Pharmaceuticals
NCT02778919Phase 2May 18, 2016Kissei Pharmaceuticals
NCT01629420Phase 2Jun 25, 2012Kissei Pharmaceuticals
NCT01533532Phase 2Feb 12, 2012Kissei Pharmaceuticals, Kwame Nkrumah University of Science and Technology
NCT01395940Phase 2Jul 14, 2011Kissei Pharmaceuticals
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Kissei PharmaceuticalsFor profit7722011
Kwame Nkrumah University of Science and TechnologyAcademic/Hospital1012012
2 organizations
Page 1 / 1